HURA ▲ +4.9% - TuHURA Biosciences, Inc. $HURA HURA - TuHURA Biosciences Receives FDA "Study May Proceed" Notice and IND Clearance for the Evaluation of its TBS-2025 VISTA-Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood-Related Cancers TuHURA Biosciences received FDA clearance to proceed with an investigational new drug (IND) application for TBS-2025, its VISTA-inhibiting antibody candidate, in molecularly defined patient populations with acute myeloid leukemia and other hematologic malignancies. The regulatory green light to advance the clinical program drove the 4.9% gain. 14-SEP-2026 07:46 AM ET